Cardiovascular & Hematological Agents in Medicinal Chemistry

Cardiovascular & Hematological Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5257
ISSN (Online): 1875-6182

Back Subscribe
Review Article

The Effect of Sri Lankan Medicinal Herbs on the Reduction of Dyslipidemia

Author(s): A.G. Nadeesha Nirmali, Sonali Marasinghe, Pandula Athauda-Arachchiorcid of author, Sampath B. Alahakoon and Anchala I. Kuruppu*

Volume 23, Issue 4, 2025

Published on: 07 July, 2025

Page: [259 - 275] Pages: 17

DOI: 10.2174/0118715257365508250627002738

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Cardiovascular disease remains a leading global cause of mortality, with dyslipidemia as a major risk factor. While conventional lipid-lowering therapies are effective, they may have adverse effects, highlighting the need for alternative approaches. With its rich biodiversity and long-standing traditional medicine practices, Sri Lanka offers a natural alternative through medicinal plants with antilipidemic properties. Many of these plants are commonly used in Sri Lankan cuisine, not only enhancing flavor but also providing bioactive compounds that regulate lipid levels. This review explores the role of Murraya koenigii, Garcinia quesita, Garcinia zeylanica, Moringa oleifera, Tamarindus indica, Piper nigrum, and Trigonella foenum-graecum in managing dyslipidemia. These plants have demonstrated lipid-lowering effects by reducing total cholesterol, LDL cholesterol, and triglycerides while increasing HDL cholesterol, enhancing fat metabolism, and exerting antioxidant and anti-inflammatory properties. The review also promotes the integration of these herbs into daily meals for cardiovascular disease management, offering a natural remedy and prevention method. By integrating traditional knowledge with scientific research, Sri Lanka can enhance its healthcare system and improve cardiovascular health outcomes.

Keywords: Cardiovascular disease, dyslipidemia, medicinal herbs, traditional medicine, antilipidemic compounds, mortality.

Graphical Abstract

[1]
Leporn, N.E.; Fouchian, D.D.; McCulloughn, P.A. New vistas for the treatment of obesity: Turning the tide against the leading cause of morbidity and cardiovascular mortality in the developed world. Rev. Cardiovasc. Med., 2013, 14(1), 20-40.
[http://dx.doi.org/10.3909/ricm0682] [PMID: 23651984]
[2]
Di Cesare, M.; Perel, P.; Taylor, S.; Kabudula, C.; Bixby, H.; Gaziano, T.A.; McGhie, D.V.; Mwangi, J.; Pervan, B.; Narula, J.; Pineiro, D.; Pinto, F.J. The heart of the world. Glob. Heart, 2024, 19(1), 11.
[http://dx.doi.org/10.5334/gh.1288] [PMID: 38273998]
[3]
Zhou, W.; Liang, Z.; Lou, X.; Wang, N.; Liu, X.; Li, R.; Pai, P. The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China: A cost-effectiveness analysis. Front. Pharmacol., 2024, 15, 1283922.
[http://dx.doi.org/10.3389/fphar.2024.1283922] [PMID: 38469404]
[4]
Thomas, H.; Diamond, J.; Vieco, A.; Chaudhuri, S.; Shinnar, E.; Cromer, S.; Perel, P.; Mensah, G.A.; Narula, J.; Johnson, C.O.; Roth, G.A.; Moran, A.E. Global atlas of cardiovascular disease 2000-2016: The path to prevention and control. Glob. Heart, 2018, 13(3), 143-163.
[http://dx.doi.org/10.1016/j.gheart.2018.09.511] [PMID: 30301680]
[5]
Bhopal, R.; Fischbacher, C.; Vartiainen, E.; Unwin, N.; White, M.; Alberti, G. Predicted and observed cardiovascular disease in South Asians: Application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data. J. Public Health., 2005, 27(1), 93-100.
[http://dx.doi.org/10.1093/pubmed/fdh202] [PMID: 15749725]
[6]
Senaviratna, N.A.M.R. Cardiovascular disease burden in a country: In the context of Sri Lanka. Eur J. Med. Health. Res., 2023, 1(3), 55-58.
[http://dx.doi.org/10.59324/ejmhr.2023.1(3).09]
[7]
Athauda-arachchi, P. Advanced interventional cardiac procedures and perioperative care required to prevent the epidemic of end-stage heart disease in Sri Lanka. Sri Lanka. J. med., 2019, 28(1), 54.
[http://dx.doi.org/10.4038/sljm.v28i1.121]
[8]
In Het Panhuis, W.; Schönke, M.; Modder, M.; Tom, H.E.; Lalai, R.A.; Pronk, A.C.M.; Streefland, T.C.M.; van Kerkhof, L.W.M.; Dollé, M.E.T.; Depuydt, M.A.C.; Bot, I.; Vos, W.G.; Bosmans, L.A.; van Os, B.W.; Lutgens, E.; Rensen, P.C.N.; Kooijman, S. Time-restricted feeding attenuates hypercholesterolaemia and atherosclerosis development during circadian disturbance in APOE*3-Leiden.CETP mice. EBioMedicine, 2023, 93, 104680.
[http://dx.doi.org/10.1016/j.ebiom.2023.104680] [PMID: 37356205]
[9]
Taher, Z.A.; Taher, A.A.; Radi, S. An update on dyslipidemia management and medications: A review. Cureus, 2024, 16(3), e56255.
[http://dx.doi.org/10.7759/cureus.56255] [PMID: 38623110]
[10]
Kaya, Ş.; Keçeci, T.; Haliloğlu, S. Effects of zinc and vitamin A supplements on plasma levels of thyroid hormones, cholesterol, glucose and egg yolk cholesterol of laying hens. Res. Vet. Sci., 2001, 71(2), 135-139.
[http://dx.doi.org/10.1053/rvsc.2001.0500] [PMID: 11883892]
[11]
Katulanda, P.; Dissanayake, H.A.; De Silva, S.D.N.; Katulanda, G.W.; Liyanage, I.K.; Constantine, G.R.; Sheriff, R.; Matthews, D.R. Prevalence, patterns, and associations of dyslipidemia among Sri Lankan adults—Sri Lanka Diabetes and Cardiovascular Study in 2005–2006. J. Clin. Lipidol., 2018, 12(2), 447-454.
[http://dx.doi.org/10.1016/j.jacl.2018.01.006] [PMID: 29429894]
[12]
Bandara, K.M.G.K.; Kumarasiri, P.V.R.; Nugegoda, D.B. Lipid profile and related factors among adolescents in an urban setting in Sri Lanka: The situation in 2006. Sri Lanka. J. med., 2016, 25(1), 11.
[http://dx.doi.org/10.4038/sljm.v25i1.14]
[13]
Huang, C.; Zhang, W.Q.; Tang, W.W.; Liu, Y.; Liu, J.X.; Xu, R.H.; Zhao, S.P.; Wang, T.D.; Huang, X.B. Prevalence and related factors of dyslipidemia among urban adults aged 35 to 79 years in Southwestern China. Sci. Rep., 2021, 11(1), 17579.
[http://dx.doi.org/10.1038/s41598-021-96864-w] [PMID: 34475467]
[14]
Ayoade, O.G.; Umoh, I.; Amadi, C. Dyslipidemia and associated risk factors among nigerians with hypertension. Dubai Medical Journal, 2020, 3(4), 155-161.
[http://dx.doi.org/10.1159/000509570]
[15]
Pasternak, R.C. 2001 National Cholesterol Education Program (NCEP) guidelines on the detection, evaluation and treatment of elevated cholesterol in adults: Adult treatment panel III (ATP III). ACC Curr. J. Rev., 2002, 11(4), 37-45.
[http://dx.doi.org/10.1016/S1062-1458(02)00670-0]
[16]
Liu, W.; Yang, C.; Lei, F.; Huang, X.; Cai, J.; Chen, S.; She, Z.G.; Li, H. Major lipids and lipoprotein levels and risk of blood pressure elevation: A Mendelian Randomisation study. EBioMedicine, 2024, 100, 104964.
[http://dx.doi.org/10.1016/j.ebiom.2023.104964] [PMID: 38181703]
[17]
Yanai, H.; Yoshida, H. Secondary dyslipidemia: Its treatments and association with atherosclerosis. Glob. Health Med., 2021, 3(1), 15-23.
[http://dx.doi.org/10.35772/ghm.2020.01078] [PMID: 33688591]
[18]
Ying, Z.; van Eenige, R.; Ge, X.; van Marwijk, C.; Lambooij, J.M.; Guigas, B.; Giera, M.; de Boer, J.F.; Coskun, T.; Qu, H.; Wang, Y.; Boon, M.R.; Rensen, P.C.N.; Kooijman, S. Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE*3-Leiden.CETP mice. EBioMedicine, 2023, 93, 104684.
[http://dx.doi.org/10.1016/j.ebiom.2023.104684] [PMID: 37379656]
[19]
Li, Z.; Zhang, B.; Liu, Q.; Tao, Z.; Ding, L.; Guo, B.; Zhang, E.; Zhang, H.; Meng, Z.; Guo, S.; Chen, Y.; Peng, J.; Li, J.; Wang, C.; Huang, Y.; Xu, H.; Wu, Y. Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease. EBioMedicine, 2023, 90, 104543.
[http://dx.doi.org/10.1016/j.ebiom.2023.104543] [PMID: 37002989]
[20]
Miklankova, D.; Markova, I.; Hüttl, M.; Malinska, H. Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia. Front. Pharmacol., 2024, 15, 1393946.
[http://dx.doi.org/10.3389/fphar.2024.1393946] [PMID: 39027339]
[21]
Herink, M.; Ito, M.K. Medication induced changes in lipid and lipoproteins; Endotext, 2000.
[22]
Zodda, D.; Giammona, R.; Schifilliti, S. Treatment strategy for dyslipidemia in cardiovascular disease prevention: Focus on old and new drugs. Pharmacy, 2018, 6(1), 10.
[http://dx.doi.org/10.3390/pharmacy6010010] [PMID: 29361723]
[23]
[24]
Karalis, D.G.; Victor, B.; Ahedor, L.; Liu, L. Use of lipid-lowering medications and the likelihood of achieving optimal ldl-cholesterol goals in coronary artery disease patients. Cholesterol, 2012, 2012, 1-7.
[http://dx.doi.org/10.1155/2012/861924] [PMID: 22888414]
[25]
Ma, X.N.; Shi, M.F.; Wang, S.I.; Feng, W.; Chen, S.L.; Zhong, X.Q.; Liu, Q.P.; Cheng-Chung Wei, J.; Lin, C.S.; Xu, Q. Risk of dyslipidemia and major adverse cardiac events with tofacitinib versus adalimumab in rheumatoid arthritis: A real-world cohort study from 7580 patients. Front. Pharmacol., 2024, 15, 1370661.
[http://dx.doi.org/10.3389/fphar.2024.1370661] [PMID: 38881871]
[26]
Ramkumar, S.; Raghunath, A.; Raghunath, S.; Raghunath, S. Statin therapy: Review of safety and potential side effects. Zhonghua Minguo Xinzangxue Hui Zazhi, 2016, 32(6), 631-639.
[http://dx.doi.org/10.6515/ACS20160611A] [PMID: 27899849]
[27]
Bansal, A.B.; Cassagnol, M. HMG-CoA Reductase Inhibitors; StatPearls Publishing: Treasure Island, FL, 2024.
[28]
Ho, C.K.M.; Walker, S.W. Statins and their interactions with other lipid-modifying medications: Safety issues in the elderly. Ther. Adv. Drug Saf., 2012, 3(1), 35-46.
[http://dx.doi.org/10.1177/2042098611428486] [PMID: 25083224]
[29]
Sizar, O.; Nassereddin, A.; Talati, R. Ezetimibe; StatPearls Publishing: Treasure Island, FL, 2024.
[30]
Maliha, M.; Satish, V.; Kumar, S.S.; Chi, K.Y.; Shama, N.; Kharawala, A.; Duarte, G.; Li, W.; Purkayastha, S.; Mangeshkar, S.; Borkowski, P.; Gashi, E.; Behuria, S. The safety profile of inclisiran in patients with dyslipidemia: A systematic review and meta-analysis. Health Care, 2025, 13(2), 141.
[http://dx.doi.org/10.3390/healthcare13020141] [PMID: 39857168]
[31]
Hansen, M.; Sonne, D.P.; Mikkelsen, K.H.; Gluud, L.L.; Vilsbøll, T.; Knop, F.K. Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. J. Diabetes Complications, 2017, 31(5), 918-927.
[http://dx.doi.org/10.1016/j.jdiacomp.2017.01.011] [PMID: 28238556]
[32]
Mazhar, F.; Haider, N. Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia. J. Pharmacol. Pharmacother., 2016, 7(4), 190-193.
[http://dx.doi.org/10.4103/0976-500X.195906] [PMID: 28163543]
[33]
Gürgöze, M.T.; Muller-Hansma, A.H.G.; Schreuder, M.M.; Galema-Boers, A.M.H.; Boersma, E.; Roeters van Lennep, J.E. Adverse events associated with PCSK 9 inhibitors: A real‐world experience. Clin. Pharmacol. Ther., 2019, 105(2), 496-504.
[http://dx.doi.org/10.1002/cpt.1193] [PMID: 30053327]
[34]
Du, Z.; Qin, Y. Dyslipidemia and cardiovascular disease: Current knowledge, existing challenges, and new opportunities for management strategies. J. Clin. Med., 2023, 12(1), 363.
[http://dx.doi.org/10.3390/jcm12010363] [PMID: 36615163]
[35]
Duarte Lau, F.; Giugliano, R.P. Adenosine triphosphate citrate lyase and fatty acid synthesis inhibition. JAMA Cardiol., 2023, 8(9), 879-887.
[http://dx.doi.org/10.1001/jamacardio.2023.2402] [PMID: 37585218]
[36]
Lincoff, A.M.; Ray, K.K.; Sasiela, W.J.; Haddad, T.; Nicholls, S.J.; Li, N.; Cho, L.; Mason, D.; Libby, P.; Goodman, S.G.; Nissen, S.E. Comparative cardiovascular benefits of bempedoic acid and statin drugs. J. Am. Coll. Cardiol., 2024, 84(2), 152-162.
[http://dx.doi.org/10.1016/j.jacc.2024.04.048] [PMID: 38960508]
[37]
Biolo, G.; Vinci, P.; Mangogna, A.; Landolfo, M.; Schincariol, P.; Fiotti, N.; Mearelli, F.; Di Girolamo, F.G. Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome. Front. Cardiovasc. Med., 2022, 9, 1028355.
[http://dx.doi.org/10.3389/fcvm.2022.1028355] [PMID: 36386319]
[38]
Brandts, J.; Ray, K.K. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: Early indications and potential. Expert Opin. Investig. Drugs, 2020, 29(8), 763-770.
[http://dx.doi.org/10.1080/13543784.2020.1778668] [PMID: 32564642]
[39]
Pahan, K. Lipid-lowering drugs. Cell. Mol. Life Sci., 2006, 63(10), 1165-1178.
[http://dx.doi.org/10.1007/s00018-005-5406-7] [PMID: 16568248]
[40]
Singh, G.; Correa, R. Fibrate Medications; StatPearls Publishing: Treasure Island, FL, 2024.
[41]
Žák, A.; Vecka, M.; Perlík, F.; Hromádka, R.; Staňková, B.; Tvrzická, E.; Žák, A. Niacin in the treatment of hyperlipidemias in light of new clinical trials: Has niacin lost its place? Med. Sci. Monit., 2015, 21, 2156-2162.
[http://dx.doi.org/10.12659/MSM.893619] [PMID: 26210594]
[42]
Ganji, S.H.; Kamanna, V.S.; Kashyap, M.L. Niacin and cholesterol: Role in cardiovascular disease (review). J. Nutr. Biochem., 2003, 14(6), 298-305.
[http://dx.doi.org/10.1016/S0955-2863(02)00284-X] [PMID: 12873710]
[43]
Djadjo, S.; Bajaj, T. Niacin; StatPearls Publishing: Treasure Island, FL, 2024.
[44]
Pirillo, A.; Catapano, A.L. Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. Atheroscler. Suppl., 2013, 14(2), 237-242.
[http://dx.doi.org/10.1016/S1567-5688(13)70004-7] [PMID: 23958479]
[45]
Ryu, H. Pharmacokinetic interactions between the fixed-dose combination of ezetimibe/rosuvastatin 10/20 mg and the fixed-dose combination of telmisartan/amlodipine 80/5 mg in healthy subjects. Drug Des. Devel. Ther., 2024, 18, 2641-2652.
[http://dx.doi.org/10.2147/DDDT.S465652] [PMID: 38974125]
[46]
Feingold, K.R. Cholesterol Lowering Drugs; Endotext, 2000.
[47]
Waisundara, V.Y. Important history of incorporation of medicinal plants into porridge in Sri Lanka.In: Traditional Herbal Remedies of Sri Lanka; CRC Press: Boca Raton, FL, 2019.
[http://dx.doi.org/10.1201/9781315181844-3]
[48]
Kuruppu, A.I.; Paranagama, P.; Goonasekara, C.L. Medicinal plants commonly used against cancer in traditional medicine formulae in Sri Lanka. Saudi Pharm. J., 2019, 27(4), 565-573.
[http://dx.doi.org/10.1016/j.jsps.2019.02.004] [PMID: 31061626]
[49]
Perera, P. Current scenario of herbal medicine in Sri Lanka. New Delhi on 14 -15 April,2012.
[50]
Balasooriya, S.J.; Sotheeswaran, S.; Balasubramanium, S. Economically useful plants of Sri Lanka Part IV* Screening of Sri Lanka Plants for Tannins. J. Natl. Sci. Found. Sri Lanka, 1982, 10(2), 213.
[http://dx.doi.org/10.4038/jnsfsr.v10i2.8430]
[51]
Tan, Z.; Halter, B.; Liu, D.; Gilbert, E.R.; Cline, M.A. Dietary flavonoids as modulators of lipid metabolism in poultry. Front. Physiol., 2022, 13, 863860.
[http://dx.doi.org/10.3389/fphys.2022.863860] [PMID: 35547590]
[52]
Siriwardhana, A.; Wijesundara, S.; Karunaratne, V. A review of studies on bioactive compounds isolated from Sri Lankan flora. J. Natl. Sci. Found. Sri Lanka, 2015, 43(1), 11.
[http://dx.doi.org/10.4038/jnsfsr.v43i1.7912]
[53]
Weerasinghe, W.P.N.W.; Deraniyagala, S.A. Antioxidant activity of some Sri Lankan endemic medicinal plants. Pharmaceutical Journal of Sri Lanka, 2016, 6(0), 9.
[http://dx.doi.org/10.4038/pjsl.v6i0.10]
[54]
Sharifi-Rad, J.; Quispe, C.; Imran, M.; Rauf, A.; Nadeem, M.; Gondal, T.A.; Ahmad, B.; Atif, M.; Mubarak, M.S.; Sytar, O.; Zhilina, O.M.; Garsiya, E.R.; Smeriglio, A.; Trombetta, D.; Pons, D.G.; Martorell, M.; Cardoso, S.M.; Razis, A.F.A.; Sunusi, U.; Kamal, R.M.; Rotariu, L.S.; Butnariu, M.; Docea, A.O.; Calina, D. Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits. Oxid. Med. Cell. Longev., 2021, 2021(1), 3268136.
[http://dx.doi.org/10.1155/2021/3268136] [PMID: 34336089]
[55]
Napagoda, M.; Prathibha, E.; Nifras, M. In vitro erythrocyte membrane stabilization potential in some Sri Lankan medicinal plant extracts. Prayogik Rasayan, 2019, 3(3)
[http://dx.doi.org/10.53023/p.rasayan-20190222]
[56]
Waisundara, V.Y.; Watawana, M.I. The classification of sri lankan medicinal herbs: An extensive comparison of the antioxidant activities. J. Tradit. Complement. Med., 2014, 4(3), 196-202.
[http://dx.doi.org/10.4103/2225-4110.126175] [PMID: 25161925]
[57]
Arseculeratne, S.N.; Gunatilaka, A.A.L.; Panabokke, R.G. Studies on medicinal plants of sri lanka. part 14: Toxicity of some traditional medicinal herbs. J. Ethnopharmacol., 1985, 13(3), 323-335.
[http://dx.doi.org/10.1016/0378-8741(85)90078-9] [PMID: 4058035]
[58]
Chen, X.Q.; Hu, T.; Han, Y.; Huang, W.; Yuan, H.B.; Zhang, Y.T.; Du, Y.; Jiang, Y.W. Preventive effects of catechins on cardiovascular disease. Molecules, 2016, 21(12), 1759.
[http://dx.doi.org/10.3390/molecules21121759] [PMID: 28009849]
[59]
Samarasekera, R.; Hemalal, K.P.; Ata, A. In pursuit of bioactive constituents from Sri Lankan medicinal plants. Planta Med., 2010, 76(5), s-0030-s-1251803.
[http://dx.doi.org/10.1055/s-0030-1251803]
[60]
Bari, M.D.N.; Ansari, M.D.R.; Anwar, M. Bioactive compounds from medicinal plants in liver disease treatment: A review. Ann. Phytomed., 2022, 11(1)
[http://dx.doi.org/10.54085/ap.2022.11.1.21]
[61]
Mohammadi-Cheraghabadi, M.; Hazrati, S. Terpenoids, steroids, and phenolic compounds of medicinal plants.In: Phytochemicals in Medicinal Plants; Arora, C.; Verma, D.K.; Aslam, J.; Mahish, P.K., Eds.; De Gruyter, 2023, pp. 105-130.
[http://dx.doi.org/10.1515/9783110791891-005]
[62]
Ray, S.; Saini, M.K. Cure and prevention of cardiovascular diseases: Herbs for heart. Clinical Phytoscience, 2021, 7(1), 64.
[http://dx.doi.org/10.1186/s40816-021-00294-0]
[63]
Gyawali, D.; Vohra, R.; Orme-Johnson, D.; Ramaratnam, S.; Schneider, R.H. A systematic review and meta-analysis of ayurvedic herbal preparations for hypercholesterolemia. Medicina, 2021, 57(6), 546.
[http://dx.doi.org/10.3390/medicina57060546] [PMID: 34071454]
[64]
Murad, S.; Niaz, K.; Aslam, H. Effects of ginger on LDL-C, total cholesterol and body weight. Clin. Med. Biochem., 2018, 4(2)
[http://dx.doi.org/10.4172/2471-2663.1000140]
[65]
Qin, S.; Huang, L.; Gong, J.; Shen, S.; Huang, J.; Ren, H.; Hu, H. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: A meta-analysis of randomized controlled trials. Nutr. J., 2017, 16(1), 68.
[http://dx.doi.org/10.1186/s12937-017-0293-y] [PMID: 29020971]
[66]
Reddy, B.M.; Dhanpal, C.K.; Lakshmi, B.V.S. A review on curry leaves (Murraya koenigii): Versatile multi-potential medicinal plant. Int. J. Adv. Pharm. Med. Bioallied Sci., 2018, 6(1), 31-41.
[67]
Jayaweera, D.M.A. Medicinal plants (Indigenous and Exotic) Used in Ceylon Part 1. 2006. Available from: [https://archive.org/details/medical_used_in_ceylon_581_na_02
[68]
Jayaweera, D.M.A. Medicinal plants (Indigenous and Exotic) Used in Ceylon Part 2. 2006. Available from: [https://dl.nsf.gov.lk/items/69292058-79c4-49a3-abbc-eac7b76805d6
[69]
Jayaweera, D.M.A. Medicinal plants (Indigenous and Exotic) Used in Ceylon Part 3. 2006. Available from: [https://dl.nsf.gov.lk/items/5bda5566-92c1-4077-8c1f-19c2332d191c
[70]
Jayaweera, D.M.A. Medicinal plants (Indigenous and Exotic) Used in Ceylon Part 4. 2006. Available from: [https://dl.nsf.gov.lk/items/a43d6e91-5ce2-4dd6-bace-3aec2eeb2d0a
[71]
Kesari, A.N.; Kesari, S.; Singh, S.K.; Gupta, R.K.; Watal, G. Studies on the glycemic and lipidemic effect of Murraya koenigii in experimental animals. J. Ethnopharmacol., 2007, 112(2), 305-311.
[http://dx.doi.org/10.1016/j.jep.2007.03.023] [PMID: 17467937]
[72]
Vasudevan, M.; Parle, M. Antiamnesic potential of Murraya koenigii leaves. Phytother. Res., 2009, 23(3), 308-316.
[http://dx.doi.org/10.1002/ptr.2620] [PMID: 18844259]
[73]
Zahin, M.; Aqil, F.; Husain, F.M.; Ahmad, I. Antioxidant capacity and antimutagenic potential of Murraya koenigii. BioMed Res. Int., 2013, 2013, 1-10.
[http://dx.doi.org/10.1155/2013/263509] [PMID: 23853769]
[74]
Lubeck, B. Garcinia cambogia: Potential Health Benefits vs. Risks. 2024. Available from: https://www.verywellhealth.com/everything-you-should-know-about-garcinia-cambogia-7565005
[75]
Nimanthika, W.J.; Kaththriarachchi, H.S. Systematics of genus Garcinia L. (Clusiaceae) in Sri Lanka: New insights from vegetative morphology. J. Natl. Sci. Found. Sri Lanka, 2010, 38(1), 29.
[http://dx.doi.org/10.4038/jnsfsr.v38i1.1723]
[76]
Semwal, R.B.; Semwal, D.K.; Vermaak, I.; Viljoen, A. A comprehensive scientific overview of Garcinia cambogia. Fitoterapia, 2015, 102, 134-148.
[http://dx.doi.org/10.1016/j.fitote.2015.02.012] [PMID: 25732350]
[77]
Hewageegana, A.; Hewageegana, H.; Arawwawala, L. Comparison on phytochemical and physicochemical parameters of Garcinia cambogia (Gaertn.) Desr. and Garcinia zeylanica Linn fruit rinds. J. Pharmacogn. Phytochem., 2018, 7(2), 2532-2535.
[78]
Garcinia Cambogia. In: In: LiverTox: Clinical and Research Information on Drug-Induced Liver; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, (MD), 2012.
[79]
Fassina, P.; Scherer Adami, F.; Terezinha Zani, V.; Kasper Machado, I.C.; Garavaglia, J.; Quevedo Grave, M.T.; Ramos, R.; Morelo Dal Bosco, S. The effect of Garcinia cambogia as coadjuvant in the weight loss process. Nutr. Hosp., 2015, 32(6), 2400-2408.
[http://dx.doi.org/10.3305/nh.2015.32.6.9587] [PMID: 26667686]
[80]
Kim, K.Y.; Lee, H.N.; Kim, Y.J.; Park, T. Garcinia cambogia extract ameliorates visceral adiposity in C57BL/6J mice fed on a high-fat diet. Biosci. Biotechnol. Biochem., 2008, 72(7), 1772-1780.
[http://dx.doi.org/10.1271/bbb.80072] [PMID: 18603810]
[81]
Mathapati, I.S; R, M.; P, P.; R H, J. Therapeutic Evaluation of Vrikshamla (Garcinia Cambogia) in the Management of Sthoulya (Obesity) W.S.R Dyslipidemia a case report. Int. J. Life. Sci. Pharma Res., 2022 (Jul);
[http://dx.doi.org/10.22376/ijpbs/lpr.2022.12.4.L97-107]
[82]
Liyanagamage, D.S.N.K.; Jayasinghe, S.; Attanayake, A.P.; Karunaratne, V.; Wijesundara, D.S.A. Antihyperglycemic activity of fruit extracts of Sri Lankan endemic species Garcinia quaesita Pierre “Rathgoraka” and its isolated compound, garcinol. Ceylon Journal of Science, 2020, 49(3), 303.
[http://dx.doi.org/10.4038/cjs.v49i3.7781]
[83]
Sampath, S.N.T.I.; Jayasinghe, S.; Attanayake, A.P.; Karunaratne, V. Sub-acute antihyperlipidemic and antihyperglycemic activity of the hexane extract of a polyherbal mixture in streptozotocin-induced diabetic rats. Ceylon J. Sci., 2021, 50(3), 279.
[http://dx.doi.org/10.4038/cjs.v50i3.7909]
[84]
Anzano, A.; Ammar, M.; Papaianni, M.; Grauso, L.; Sabbah, M.; Capparelli, R.; Lanzotti, V. Moringa oleifera Lam.: A phytochemical and pharmacological overview. Horticulturae, 2021, 7(10), 409.
[http://dx.doi.org/10.3390/horticulturae7100409]
[85]
Milla, P.G.; Peñalver, R.; Nieto, G. Health benefits of uses and applications of Moringa oleifera in bakery products. Plants, 2021, 10(2), 318.
[http://dx.doi.org/10.3390/plants10020318] [PMID: 33562157]
[86]
Mbikay, M. Therapeutic potential of Moringa oleifera leaves in chronic hyperglycemia and dyslipidemia: A review. Front. Pharmacol., 2012, 3, 24.
[http://dx.doi.org/10.3389/fphar.2012.00024] [PMID: 22403543]
[87]
Leone, A.; Spada, A.; Battezzati, A.; Schiraldi, A.; Aristil, J.; Bertoli, S. Cultivation, genetic, ethnopharmacology, phytochemistry and pharmacology of Moringa oleifera leaves: An overview. Int. J. Mol. Sci., 2015, 16(6), 12791-12835.
[http://dx.doi.org/10.3390/ijms160612791] [PMID: 26057747]
[88]
Jain, P.G.; Patil, S.D.; Haswani, N.G.; Girase, M.V.; Surana, S.J. Hypolipidemic activity of Moringa oleifera Lam., Moringaceae, on high fat diet induced hyperlipidemia in albino rats. Rev. Bras. Farmacogn., 2010, 20(6), 969-973.
[http://dx.doi.org/10.1590/S0102-695X2010005000038]
[89]
Nambiar, V.; Guin, P.; Parnami, S.; Daniel, M. Impact of antioxidants from drumstick leaves on the lipid profile of hyperlipidemics. J. Herb Med. Toxicol., 2010, 4, 165-172.
[90]
Yahia, E.M.; Salih, N.K-E. Tamarind (Tamarindus indica L.).In: Postharvest Biology and Technology of Tropical and Subtropical Fruits; Elsevier, 2011, pp. 442-458e.
[http://dx.doi.org/10.1533/9780857092618.442]
[91]
Lim, C.Y.; Mat Junit, S.; Abdulla, M.A.; Abdul Aziz, A. In vivo biochemical and gene expression analyses of the antioxidant activities and hypocholesterolaemic properties of Tamarindus indica fruit pulp extract. PLoS One, 2013, 8(7), e70058.
[http://dx.doi.org/10.1371/journal.pone.0070058] [PMID: 23894592]
[92]
Uchenna, U.E.; Shori, A.B.; Baba, A.S. Tamarindus indica seeds improve carbohydrate and lipid metabolism: An in vivo study. J. Ayurveda Integr. Med., 2018, 9(4), 258-265.
[http://dx.doi.org/10.1016/j.jaim.2017.06.004] [PMID: 29203351]
[93]
Thahira Banu, A.; Aswini, M. Role of Piper nigrum in functional food and nutraceuticals.In: Herbs, Spices and Their Roles in Nutraceuticals and Functional Foods; Elsevier, 2023, pp. 41-60.
[http://dx.doi.org/10.1016/B978-0-323-90794-1.00019-3]
[94]
Mittal, R.; Gupta, R.L. In vitro antioxidant activity of piperine. Methods Find. Exp. Clin. Pharmacol., 2000, 22(5), 271-274.
[http://dx.doi.org/10.1358/mf.2000.22.5.796644] [PMID: 11031726]
[95]
Duangjai, A.; Ingkaninan, K.; Praputbut, S.; Limpeanchob, N. Black pepper and piperine reduce cholesterol uptake and enhance translocation of cholesterol transporter proteins. J. Nat. Med., 2013, 67(2), 303-310.
[http://dx.doi.org/10.1007/s11418-012-0682-7] [PMID: 22736065]
[96]
Vijayakumar, R.S.; Surya, D.; Senthilkumar, R.; Nalini, N. Hypolipidemic effect of black pepper (Piper nigrum Linn.) in rats fed high fat diet. J. Clin. Biochem. Nutr., 2002, 32, 31-42.
[http://dx.doi.org/10.3164/jcbn.32.31]
[97]
Ashokkumar, K.; Murugan, M.; Dhanya, M.K.; Pandian, A.; Warkentin, T.D. Phytochemistry and therapeutic potential of black pepper [Piper nigrum (L.)] essential oil and piperine: A review. Clinical Phytoscience, 2021, 7(1), 52.
[http://dx.doi.org/10.1186/s40816-021-00292-2]
[98]
Singh, N.; Yadav, S.S.; Kumar, S.; Narashiman, B. Ethnopharmacological, phytochemical and clinical studies on Fenugreek (Trigonella foenum-graecum L.). Food Biosci., 2022, 46, 101546.
[http://dx.doi.org/10.1016/j.fbio.2022.101546]
[99]
Goyal, S.; Gupta, N.; Chatterjee, S. Investigating therapeutic potential of Trigonella foenum-graecum L. as our defense mechanism against several human diseases. J. Toxicol., 2016, 2016, 1-10.
[http://dx.doi.org/10.1155/2016/1250387] [PMID: 26884758]
[100]
Kumar, P.; Bhandari, U.; Jamadagni, S. Fenugreek seed extract inhibit fat accumulation and ameliorates dyslipidemia in high fat diet-induced obese rats. BioMed Res. Int., 2014, 2014, 1-11.
[http://dx.doi.org/10.1155/2014/606021] [PMID: 24868532]

Rights & Permissions Print Cite